Inhibition of human eosinophil chemotaxis and of the IgE-dependent stimulation of human blood platelets by cetirizine.
Cetirizine is a new anti-allergic compound with a potent, long-acting, and specific antihistaminic property. Strongly active in the therapy of urticaria and seasonal or perennial rhinitis, it has been shown to inhibit the in vivo eosinophil attraction at skin sites challenged with allergen in atopic patients. In the present work, we confirmed that, at a therapeutical concentration, this molecule had a potent inhibitory action in vitro on eosinophil chemotaxis induced either by N-formyl-Met-Leu-Phe or platelet-activating factor and also on the IgE-dependent stimulation of platelets. These observations appear in favour of a possible role for cetirizine in the modulation of inflammatory cell interactions in allergic processes.
De Vos
C
C
Centre d'Immunologie et de Biologie Parasitaire, Unité mixte INSERM 167-CNRS 624-Institut Pasteur, Lille, France.
Joseph
M
M
Leprevost
C
C
Vorng
H
H
Tomassini
M
M
Capron
M
M
Capron
A
A
D001792:Blood Platelets / Q000502:physiology*; D017332:Cetirizine; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D002744:Chlorpheniramine / Q000494:pharmacology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004804:Eosinophils / Q000187:drug effects*; D006801:Humans; D006919:Hydroxyzine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006967:Hypersensitivity / Q000276:immunology; D007073:Immunoglobulin E / Q000276:immunology*; D066298:In Vitro Techniques; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000494:pharmacology
D010972:Platelet Activating Factor; D006919:Hydroxyzine; D007073:Immunoglobulin E; C018904:dexchlorpheniramine; D002744:Chlorpheniramine; D009240:N-Formylmethionine Leucyl-Phenylalanine; D017332:Cetirizine